Natural history and management of hepatitis C infection after liver transplantation

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 2, 2004, Pages 79-88

  Charlton, Michael ^a   Wiesner, Russell ^a  

^a MAYO CLINIC   (United States)

Author keywords

HCV management; HCV natural history

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANEMIA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT REJECTION; HEMOLYSIS; HEPATITIS C; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SCORING SYSTEM; SURVIVAL; THROMBOCYTOPENIA;

DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULINS; INTERFERON ALFA-2A; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN;

EID: 4444325299     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832932     Document Type: Review

References (73)

1. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future healthcare burden from hepatitis C in the United States. Hepatology 1998;28:390A
2. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820
3. Nery J, Esquenazi V, Weppler D, et al. Hepatitis C in liver transplantation: preliminary study of prognostic factors. Transpl Int 1994;7(Suppl 1):S229-S231
4. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177
5. Boker KHW, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25:203-210
6. Bonilla Guerrero R, Batts KP, Burgart LJ, et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000;13:229-237
7. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-687
8. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29:1220-1226
9. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625
10. Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000;6:553-561
11. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684
12. Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis following orthotopic liver transplantation. Hepatology 1996;23:971-976
13. Lim H, Lau G, Davis GL, et al. Cholestatic hepatitis leading to hepatic failure in a patient with organ transmitted hepatitis C virus infection. Gastroenterology 1994;106:248-251
14. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-678
15. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896
16. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830
17. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-1130
18. Gordon FD, Poterucha JJ, Germer J, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997; 63:1419-1423
19. Vargas HE, Laskus T, Wang LF, et al. The influence of hepatitis C virus genotype on the outcome of liver transplantation. Liver Transpl Surg 1998;4:22-27
20. Sanchez-Fueyo A, Gimenez-Barcons M, Puig-Basagoiti F, et al. Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J Med Virol 2001; 65:266-275
21. Sullivan DG, Wilson JJ, Carithers RL Jr, et al. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998;72:10036-10042
22. Hayashi J, Furusyo N, Ariyama I, et al. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 2000;181:1523-1527
23. Berenguer M, Crippin J, Bass N, et al. Proposed strategy to reduce posttransplant HCV related disease progression. Hepatology 2001;34:407A
24. Cotler SJ, Gaur LK, Gretch DR, et al. Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Tissue Antigens 1998;52:435-443
25. Prieto M, Nicolas D, Rayon JM, et al. Donor-recipient HLA matching does not predict accelerated progression of hepatitis C following liver transplantation in genotype 1b infection. Hepatology 2000;32:261
26. Min AD, Saxena R, Thung SN, et al. Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. Am J Gastroenterol 1998;93:2148-2153
27. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2004; (in press)
28. Burak KW, Kremers WK, Batts K, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcome after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-369
29. Pirenne J, Decaluwe H, Aerts R, et al. Patients transplanted for hepatitis C should not receive livers from older donors. Hepatology 2001;34:408A
30. Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000;6:407-412
31. Taniguchi M, Wachs M, Bak T, et al. Hepatitis C recurrence in living donor liver transplantation. Am J Transplant 2002; 2:138
32. Ghobrial RM, Amerst F, Farmer DG, et al. Rapid and severe early HCV recurrence following adult living donor liver transplantation. Am J Transplant 2002;2:163
33. Papatheodoridis GV, Davies S, Dhillon AP, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001;72:412-418
34. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34
35. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999;5:S107-S114
36. Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viraemia; a risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64: 721-726
37. Crippin JS, McCashland TM, Terrault NA, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355
38. Everson GT, Trouillot T, Trotter J, et al. Treatment of decompensated cirrhotics with a low-accelerating dose regimen (LADR) of interferon-alfa-2B plus ribavirin: safety and efficacy. Hepatology 2000;32:595A
39. Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-779
40. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-838
41. Gane EJ, Tibbs CJ, Ramage JK, et al. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995;8:61-64
42. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-1407
43. Cattral MS, Hemming AW, Wanless IR, et al. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 1999;67:1277-1280
44. Quadri R, Giostra E, Roskams T, et al. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 2002;73:373-378
45. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-504
46. McHutchison JG, Gordon SC, Schiff ER. Hepatitis Interventional Therapy Group Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
47. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499
48. Mazzaferro V, Regalia E, Pulvirenti A, et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-521
49. Kapur A, Rodriguez MJ, Schecter P, et al. Interferon alfa and ribavirin in established post liver transplant recurrent hepatitis C infection. Gastroenterology 1998;114:A1268
50. Giostra E, Kullak-Ublick G, Keller W, et al. Ribavirin/interferon-alfa sequential treatment of recurrent hepatitis C after liver transplantation. Hepatology 2001;34:641A
51. Lavezzo B, Rizzetto M, Smedile A, et al. Combination therapy of interferon alfa 2b and ribavirin for recurrent hepatitis C after liver transplantation. J Hepatol 1999; 30:67
52. El-Amin OA, Poterucha J, Zein N, et al. Interferon and ribavirin therapy for recurrent hepatitis C after liver transplantation. Hepatology 1999;30:247A
53. Wasserman R, Brau N, Hassanein T, et al. Once weekly epoetin alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/IFN therapy. Hepatology 2000;32:368A
54. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680
55. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672
56. Fried MW, Shiffman ML, Reddy KR, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively controlled, multicenter study. Gastroenterology 2001;120:A55
57. Manns M, McHutchison JG, Gordon SC, et al. Peginterferon alfa 2-B plus ribavirin compared to interferon interferon alfa 2-B plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial. Hepatology 2000;32: 552A
58. Ferenci P, Peck-Radosavljevic M, Vogel W, et al. 40 kDa peginterferon alfa-2a (Pegasys) in post-liver transplant recipients with established recurrent hepatitis C: preliminary results of a randomized multicenter trial. Hepatology 2001; 34:406A
59. Manzarbeitia C, Tepermann L, Chalasani N, et al. 40 KDa peginterferon alfa-2a (Pegasys) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT): preliminary results of a randomized multicenter trial. Hepatology 2001;34:406A
60. Vargas HE, Rosati MJ, Douglas DD, et al. Combination pegylated interferon alpha-2b and ribavirin in transplant patients with recurrent hepatitis C infection: a preliminary report. Hepatology 2001;34:407A
61. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects. Hepatology 1995;22:1084-1089
62. Vargas V, Charco R, Castells L, et al. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplant Proc 1995;27:1222-1223
63. de Vera ME, Smallwood GA, Davis L, et al. Interferon-A and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Hepatology 2000;32:516A
64. Feray C, Gigou M, Samuel D, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998;128:810-816
65. Manzarbeitia C, Kaul V, Zaeri N, et al. Is interferon monotherapy useful in a subset of liver transplant recipients with hepatitis C recurrence? Hepatology 2001;34:638A
66. Cotler SJ, Ganger DR, Kaur S, et al. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation 2001;71:261-266
67. Casanovas T, Ramos E, Serrano T, et al. Pilot study with the combination of interferon alfa and ribavirin for recurrent post-liver transplantation hepatitis C. Causes of treatment failure in two different populations. Hepatology 2001;34: 291A
68. Gotz G, Schon MR, Haefker A, et al. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. Transplant Proc 1998;30:2104-2106
69. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-190
70. Fischer L, Sterneck M, Valentin-Gamazo C, et al. Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha. Transplant Proc 1999;31:494-495
71. Ahmad J, Weck K, Shakil AO. Correlation of HCV genomic diversity with outcome after liver transplantation. Hepatology 2001;34:561A
72. De Vera ME, Smallwood GA, Rosado K, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-686
73. Menon KVN, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002;8:623-629